Vivo funds report 0% stake in Cidara
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman Fund, L.P. and their related LLCs filed an amended Schedule 13G stating they no longer own any common stock of Cidara Therapeutics, Inc. Following completion of the issuer’s merger on January 7, 2026, each reporting person shows 0 shares beneficially owned and 0% of the class, with no voting or dispositive power remaining.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does this Schedule 13G/A filing disclose about Cidara Therapeutics (CDTX)?
Who are the reporting persons in this Cidara Therapeutics (CDTX) Schedule 13G/A?
What is the reported ownership percentage of Cidara (CDTX) by Vivo Opportunity entities?
What type of security is covered in this Cidara Therapeutics (CDTX) Schedule 13G/A?
What certification do the Vivo Opportunity entities make in this Cidara (CDTX) filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.